ReviewBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2013
Biotechnology of polyketides: new breath of life for the novel antibiotic genetic pathways discovery through metagenomics.
Review in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Genomic determinants of antifungal activity ofFrontiers in microbiology · 2026Article
- Bacillus velezensis FiA2 as an Oxydifficidin-Producing Strain and its Effects on the Growth Performance, Immunity, Intestinal Microbiota, and Resistance to Aeromonas salmonicida Infection in Carassius carassius.Probiotics and antimicrobial proteins · 2025Article
- Profiling of Pharmaceutical Sludge Microbiome, Resistome and Secondary Metabolites Using Metagenomics.Indian journal of microbiology · 2025Article
- Secondary Metabolites fromCurrent research in microbial sciences · 2025Review
- Isolation and Whole Genome Sequence Analysis ofJournal of genomics · 2025Article
- Engineering a carbon source-responsive promoter for improved biosynthesis in the non-conventional yeastMetabolic engineering communications · 2024Article
- Exploring the Trends in Actinobacteria as Biological Control Agents of Phytopathogenic Fungi: A (Mini)-Review.Indian journal of microbiology · 2024Review
- Genomic insights into an endophyticFrontiers in microbiology · 2024Article
- Classification and Multifaceted Potential of Secondary Metabolites Produced byMolecules (Basel, Switzerland) · 2023Review
- Gut microbiota were altered with platelet count and red blood cell count in immune thrombocytopenia patients with different treatments.Frontiers in cellular and infection microbiology · 2023Article
- Enhanced production of acetyl-CoA-based products via peroxisomal surface display inProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Article
- Broad thermal spectrum metagenomic laccase with action for dye decolorization and fentin hydroxide treatment.AMB Express · 2022Article
- The Unexplored Wealth of Microbial Secondary Metabolites: the Sphingobacteriaceae Case Study.Microbial ecology · 2022Article
- Genome Characterization and Probiotic Potential ofMicroorganisms · 2022Article
- Crosstalk between the oral microbiota, mucosal immunity, and the epithelial barrier regulates oral mucosal disease pathogenesis.Mucosal immunology · 2021Review
- A Review on the Biotechnological Applications of the Operational GroupMicroorganisms · 2021Review
- Prediction and analysis of metagenomic operons via MetaRon: a pipeline for prediction of Metagenome and whole-genome opeRons.BMC genomics · 2021Article
- Dynamic Changes in Lung Microbiota of Broilers in Response to Aging and Ammonia Stress.Frontiers in microbiology · 2021Article
- Insights into the Role of Ketoreductases in the Biosynthesis of Partially Reduced Bacterial Aromatic Polyketides.Chembiochem : a European journal of chemical biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of secondary metabolites produced by microorganisms (e.g., penicillin in 1928) and the beginning of their industrial application (1940) opened new doors to what has been the main medication source for the treatment of infectious diseases and tumors. In fact, approximately 80 years after the discovery of the first antibiotic compound, and despite all of the warnings about the failure of the "goose that laid the golden egg," the potential of this wealth is still inexorable: simply adjust the focus from "micro" to "nano", that means changing the look from microorganisms to nanograms of DNA. Then, the search for new drugs, driven by genetic engineering combined with metagenomic strategies, shows us a way to bypass the barriers imposed by methodologies limited to isolation and culturing. However, we are far from solving the problem of supplying new molecules that are effective against the plasticity of multi- or pan-drug-resistant pathogens. Although the first advances in genetic engineering date back to 1990, there is still a lack of high-throughput methods to speed up the screening of new genes and design new molecules by recombination of pathways. In addition, it is necessary an increase in the variety of heterologous hosts and improvements throughout the full drug discovery pipeline. Among numerous studies focused on this subject, those on polyketide antibiotics stand out for the large technical-scientific efforts that established novel solutions for the transfer/engineering of major metabolic pathways using transposons and other episomes, overcoming one of the main methodological constraints for the heterologous expression of major pathways. In silico prediction analysis of three-dimensional enzymatic structures and advances in sequencing technologies have expanded access to the metabolic potential of microorganisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.